Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days. Over the following three weeks, no new lesions developed, further highlighting the potential of HT-001 as an effective and safe therapy for EGFRI-associated PPEs. NEW YORK Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing next-generation therapies for unmet medical needs, is excited to announce positive data from the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs) with its novel therapeutic HT-001. During this first-of-its-kind human patient case, the patient was able to cease trea
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer TherapeuticPR Newswire
- Hoth Therapeutics regains compliance with Nasdaq [Seeking Alpha]Seeking Alpha
- Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsPR Newswire
HOTH
Analyst Actions
- 1/23/25 - HC Wainwright
HOTH
Sec Filings
- 2/7/25 - Form 8-K
- 2/7/25 - Form 424B5
- 1/24/25 - Form 8-K
- HOTH's page on the SEC website